Rystiggo®

Understanding Rystiggo®

Rystiggo® is a monoclonal antibody used to treat generalized myasthenia gravis (gMG) in adults who are positive for anti-AChR (acetylcholine receptor) or anti-MuSK (muscle-specific kinase) antibodies. It works by reducing harmful autoantibodies that attack the connection between nerves and muscles.

Rystiggo® achieves this by blocking the neonatal Fc receptor (FcRn), thereby reducing circulating IgG autoantibodies at the neuromuscular junction. This mechanism helps improve muscle strength and reduces the symptoms associated with myasthenia gravis.

How Rystiggo® Works:

• Targets the FcRn receptor to reduce harmful IgG autoantibodies
• Restores nerve-muscle communication, improving muscle strength
• Reduces symptoms and enhances daily function for individuals with generalized myasthenia gravis (gMG)

FDA Approval:

• Rystiggo®: Approved on June 26, 2023

For more information, please visit the Rystiggo® patient website and speak with your healthcare provider to determine if Rystiggo® is the right treatment option for you.